Hepatotoxicity After Continuous Amiodarone Infusion in a Postoperative Cardiac Infant

Abstract

A former 34-week-old female infant with Down syndrome underwent surgical correction of a congenital heart defect at 5 months of age. Her postoperative course was complicated by severe pulmonary hypertension and junctional ectopic tachycardia. Following treatment with amiodarone infusion, she developed laboratory indices of acute liver injury. At their peak, liver transaminase levels were 19 to 35 times greater than the upper limit of normal. Transaminitis was accompanied by coagulopathy, hyperammonemia, and high serum lactate and lipid levels. Hepatic laboratory abnormalities began to resolve within 48 hr of stopping amiodarone infusion. Heart rate control was achieved concurrently with discovery of laboratory test result abnormalities, and no further antiarrhythmic therapy was required. The intravenous formulation of amiodarone contains the diluent polysorbate 80, which may have hepatotoxic effects. Specifically, animal studies suggest that polysorbate 80 may destabilize cell membranes and predispose to fatty change within liver architecture. Polysorbate was implicated in infant fatalities from Eferol use in the 1980s. This case illustrates a possible adverse event by the Naranjo probability scale. Given the extent of clinically apparent hepatic injury, this patient was not rechallenged with amiodarone during the remainder of her hospitalization. With amiodarone now used as first-line pharmacologic therapy for critical tachyarrhythmia in this population, the number of children exposed to this drug should be expected to increase. Laboratory indices of liver function should be evaluated at initiation of amiodarone therapy, as well as frequently throughout duration of therapy. Consideration should be given to polysorbate-free formulation of intravenous amiodarone for use in the cohort with congenital cardiac disease.INDEX TERMS amiodarone, congenital heart disease, hepatotoxicity, junctional ectopic tachycardia, polysorbate 80

Acute Hepatotoxicity of Intravenous Amiodarone

“…Finally, 8 cases were collected (Table 2). 8,[10][11][12][13][14] According to the currently available documentation, hepatotoxicity usually occurs within 24 hours after starting IV amiodarone administration, but sometimes after more than 3 days. 8 It usually recovers gradually after discontinuing IV amiodarone.…”

Pediatric Safety of Polysorbates in Drug Formulations

“…Since the recall of E-Ferol, there has been no such pervasive episode of PS80 toxicity, but case reports in pediatric patients have appeared periodically [31][32][33]. In Belgium, an initially healthy newborn experienced acute cardiogenic shock and multiple organ failure after receiving intravenous amiodarone at a loading dose (47 mg/kg) that was intended for oral administration-approximately 9-fold higher than the appropriate amount for intravenous infusion, underscoring the significance of properly dosing excipients for young patients [34].…”

Predictors of intravenous amiodarone induced liver injury

“…However, the available data regarding acute hepatotoxicity form intravenous (IV) amiodarone are not far beyond case reports. 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 The mechanisms of liver injury with IV amiodarone are controversial. Ischemic injury due to compromised hemodynamic conditions may have a role.…”